Literature DB >> 35503717

International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions.

Nicola Specchio1, Elaine C Wirrell2, Ingrid E Scheffer3, Rima Nabbout4, Kate Riney5,6, Pauline Samia7, Marilisa Guerreiro8, Sam Gwer9, Sameer M Zuberi10, Jo M Wilmshurst11, Elissa Yozawitz12, Ronit Pressler13, Edouard Hirsch14, Sam Wiebe15, Helen J Cross16, Emilio Perucca17,18, Solomon L Moshé19, Paolo Tinuper20,21, Stéphane Auvin22.   

Abstract

The 2017 International League Against Epilepsy classification has defined a three-tier system with epilepsy syndrome identification at the third level. Although a syndrome cannot be determined in all children with epilepsy, identification of a specific syndrome provides guidance on management and prognosis. In this paper, we describe the childhood onset epilepsy syndromes, most of which have both mandatory seizure type(s) and interictal electroencephalographic (EEG) features. Based on the 2017 Classification of Seizures and Epilepsies, some syndrome names have been updated using terms directly describing the seizure semiology. Epilepsy syndromes beginning in childhood have been divided into three categories: (1) self-limited focal epilepsies, comprising four syndromes: self-limited epilepsy with centrotemporal spikes, self-limited epilepsy with autonomic seizures, childhood occipital visual epilepsy, and photosensitive occipital lobe epilepsy; (2) generalized epilepsies, comprising three syndromes: childhood absence epilepsy, epilepsy with myoclonic absence, and epilepsy with eyelid myoclonia; and (3) developmental and/or epileptic encephalopathies, comprising five syndromes: epilepsy with myoclonic-atonic seizures, Lennox-Gastaut syndrome, developmental and/or epileptic encephalopathy with spike-and-wave activation in sleep, hemiconvulsion-hemiplegia-epilepsy syndrome, and febrile infection-related epilepsy syndrome. We define each, highlighting the mandatory seizure(s), EEG features, phenotypic variations, and findings from key investigations.
© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Entities:  

Keywords:  Landau-Kleffner syndrome; Lennox-Gastaut syndrome; Panayiotopoulos syndrome; benign occipital epilepsy; childhood epilepsy with centrotemporal spikes; continuous spike-and-wave in sleep; eyelid myoclonia; febrile infection-related epilepsy syndrome; hemiconvulsion-hemiplegia-epilepsy syndrome; myoclonic absences; myoclonic atonic

Mesh:

Year:  2022        PMID: 35503717     DOI: 10.1111/epi.17241

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  5 in total

Review 1.  The Interaction Between Sleep and Epilepsy.

Authors:  Annie H Roliz; Sanjeev Kothare
Journal:  Curr Neurol Neurosci Rep       Date:  2022-07-08       Impact factor: 6.030

2.  A peculiar family with recurrent self-limited epileptic syndrome and associated developmental disorders in six girls.

Authors:  I Cursio; N Ronzano; M Asunis; M S Dettori; S Cossu; S Murru; M Cau; F Incani; D Mei; C Bianchini; M Scioni; D Pruna
Journal:  Epilepsy Behav Rep       Date:  2022-04-22

3.  Diagnostic utility of specific abnormal EEG patterns in children for determining epilepsy phenotype and presence of structural brain abnormalities.

Authors:  Mohammed Ashour; Erica Minato; Abdulla Alawadhi; Saoussen Berrahmoune; Elisabeth Simard-Tremblay; Chantal Poulin; Kenneth A Myers
Journal:  Heliyon       Date:  2022-08-10

Review 4.  EEG biomarkers for the diagnosis and treatment of infantile spasms.

Authors:  Blanca Romero Milà; Kavyakantha Remakanthakurup Sindhu; John R Mytinger; Daniel W Shrey; Beth A Lopour
Journal:  Front Neurol       Date:  2022-07-28       Impact factor: 4.086

Review 5.  Concise Review: Stem Cell Models of SCN1A-Related Encephalopathies-Current Perspective and Future Therapies.

Authors:  Valery Zayat; Roza Szlendak; Dorota Hoffman-Zacharska
Journal:  Cells       Date:  2022-10-04       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.